Recce Pharmaceuticals Ltd
RECEF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.22 | -0.22 | -0.04 |
| FCF Yield | -16.52% | -3.13% | -3.55% | -5.46% |
| EV / EBITDA | -6.18 | -32.14 | -14.91 | -12.67 |
| Quality | ||||
| ROIC | -104.88% | -45,515.94% | 116.76% | -776.65% |
| Gross Margin | -265.42% | -20.79% | 0.00% | 91.88% |
| Cash Conversion Ratio | 0.99 | 0.90 | 0.64 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | 53.04% | 98.08% | 55.30% | 55.54% |
| Free Cash Flow Growth | -94.86% | -6.36% | 1.46% | -162.27% |
| Safety | ||||
| Net Debt / EBITDA | -0.02 | -0.40 | 0.30 | 0.41 |
| Interest Coverage | 0.00 | -21.89 | -21.74 | -35.01 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -25.93 | -35.26 | -2,058.18 | -764.38 |